Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy

Lara Falcucci, Christopher M. Dooley, Douglas Adamoski, Thomas Juan, Justin Martinez, Angelina M. Georgieva, Kamel Mamchaoui, Cansu Cirzi and Didier Y. R. Stainier ()
Additional contact information
Lara Falcucci: Max Planck Institute for Heart and Lung Research
Christopher M. Dooley: Max Planck Institute for Heart and Lung Research
Douglas Adamoski: Max Planck Institute for Heart and Lung Research
Thomas Juan: Max Planck Institute for Heart and Lung Research
Justin Martinez: Max Planck Institute for Heart and Lung Research
Angelina M. Georgieva: Max Planck Institute for Heart and Lung Research
Kamel Mamchaoui: Centre de Recherche en Myologie
Cansu Cirzi: Max Planck Institute for Heart and Lung Research
Didier Y. R. Stainier: Max Planck Institute for Heart and Lung Research

Nature, 2025, vol. 639, issue 8054, 493-502

Abstract: Abstract Duchenne muscular dystrophy (DMD) is a muscle-degenerating disease caused by mutations in the DMD gene, which encodes the dystrophin protein1,2. Utrophin (UTRN), the genetic and functional paralogue of DMD, is upregulated in some DMD patients3–5. To further investigate this UTRN upregulation, we first developed an inducible messenger RNA (mRNA) degradation system for DMD by introducing a premature termination codon (PTC) in one of its alternatively spliced exons. Inclusion of the PTC-containing exon triggers DMD mutant mRNA decay and UTRN upregulation. Notably, blocking nonsense-mediated mRNA decay results in the reversal of UTRN upregulation, whereas overexpressing DMD does not. Furthermore, overexpressing DMDPTC minigenes in wild-type cells causes UTRN upregulation, as does a wild-type DMD minigene containing a self-cleaving ribozyme. To place these findings in a therapeutic context, we used splice-switching antisense oligonucleotides (ASOs) to induce the skipping of out-of-frame exons of DMD, aiming to introduce PTCs. We found that these ASOs cause UTRN upregulation. In addition, when using an ASO to restore the DMD reading frame in myotubes derived from a DMDΔE52 patient, an actual DMD treatment, UTRN upregulation was reduced. Altogether, these results indicate that an mRNA decay-based mechanism called transcriptional adaptation6–8 plays a key role in UTRN upregulation in DMDPTC patients, and they highlight an unexplored therapeutic application of ASOs, as well as ribozymes, in inducing genetic compensation via transcriptional adaptation.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-024-08539-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:639:y:2025:i:8054:d:10.1038_s41586-024-08539-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-024-08539-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().